TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. The company offers drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (oral) for treatment of Helicobacter pylori infection, bacterial vaginosis, difficile infection; TNP-1232 for treatment of Helicobacter pylori infection; Rifasutenizole (injectable) for acute bacterial skin and skin structure infection, prosthetic joint infection, and left ventricular assist device infection; and TNP- 2092 for the treatment of diabetic foot infection. It also provides TNP-2092 (oral) for the treatment of hepatic encephalopathy and irritable bowel syndrome with diarrhea; TNBm-1, a broad spectrum bifunctional small molecule drug for metabolic disease; and TNBi-2 broad spectrum multi-targeting small molecule drug for Nontuberculous mycobacterial pulmonary disease. The company was founded in 2012 and is headquartered in Suzhou, China.